Tyzavan is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 6 US drug patents filed from 2020 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 06, 2035. Details of Tyzavan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10039804 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
| US10849956 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
| US10188697 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
| US11517609 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
| US12161690 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
| US11628200 | Glycopeptide compositions |
Nov, 2035
(10 years from now) | Active |
Several oppositions have been filed on Tyzavan's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Tyzavan's generic, the next section provides detailed information on ongoing and past EP oppositions related to Tyzavan patents.
Tyzavan's Oppositions Filed in EPO
Tyzavan has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 01, 2020, by Df-Mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte Parg Mbb. This opposition was filed on patent number EP15791287A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15791287A | Oct, 2020 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Revoked |
US patents provide insights into the exclusivity only within the United States, but Tyzavan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tyzavan's family patents as well as insights into ongoing legal events on those patents.
Tyzavan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tyzavan's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 06, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tyzavan Generic API suppliers:
Vancomycin Hydrochloride is the generic name for the brand Tyzavan. 30 different companies have already filed for the generic of Tyzavan, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tyzavan's generic
Alternative Brands for Tyzavan
There are several other brand drugs in the same treatment category and using the same active ingredient (Vancomycin Hydrochloride) as Tyzavan. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Hikma |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Vancomycin Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Azurity |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Vancomycin Hydrochloride, Tyzavan's active ingredient. Check the complete list of approved generic manufacturers for Tyzavan
About Tyzavan
Tyzavan is a drug owned by Hikma Pharmaceuticals Usa Inc. Tyzavan uses Vancomycin Hydrochloride as an active ingredient. Tyzavan was launched by Hikma in 2019.
Approval Date:
Tyzavan was approved by FDA for market use on 15 February, 2019.
Active Ingredient:
Tyzavan uses Vancomycin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Vancomycin Hydrochloride ingredient
Dosage:
Tyzavan is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 500MG BASE/100ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1GM BASE/200ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 2GM BASE/400ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 750MG BASE/150ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |
| EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) | SOLUTION | Prescription | INTRAVENOUS |